Stimulant medication is tolerated well by young cancer survivors

07/14/2009 | Medscape (free registration)

Methylphenidate, used to improve cognitive impairment in pediatric cancer survivors, is generally well tolerated, according to a study in Pediatrics that looked at two doses of the drug in a group of 103 childhood cancer survivors. They noted a subgroup of patients was at increased risk of side effects and might need a lower dosage.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care